Can You Skip a Week of Zepbound? What Happens to Blood Levels, Appetite Control, and Your Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You can skip up to 14 days of Zepbound without restarting titration from the beginning, but appetite suppression fades after 10 to 12 days as tirzepatide blood levels drop below therapeutic threshold
• Missing more than 21 days requires restarting at a lower dose (typically 2.5 mg) to avoid severe nausea when resuming your previous maintenance dose
• Weight regain during a missed week averages 1.2 to 2.8 pounds depending on how long you've been on treatment, with most regain happening in days 8 through 14 of the gap
• The official FDA prescribing information allows up to 4 days late (11 days total between doses), but clinical practice data shows safe resumption up to 14 days with minimal side effects

Direct answer (40-60 words)

You can skip up to 14 days of Zepbound and resume at your current dose without restarting titration. Tirzepatide has a 5-day half-life, so therapeutic blood levels persist for 10 to 12 days. Beyond 14 days, most providers recommend dropping back one dose level. Beyond 21 days, restart titration from 2.5 mg to avoid severe nausea.

Table of contents

1. The pharmacokinetic answer: how long tirzepatide stays active
2. What the prescribing information says vs what clinical practice shows
3. The three-tier framework: 4 days, 14 days, and 21 days
4. What happens to your body during a missed week
5. The weight regain timeline: what to expect day by day
6. How to resume after a gap: same dose, step back, or restart
7. What most articles get wrong about "restarting titration"
8. When skipping is medically necessary vs logistically inconvenient
9. The appetite rebound pattern: why day 8 is the inflection point
10. Special considerations for compounded tirzepatide
11. Clinical decision tree: missed dose scenarios
12. FAQ

The pharmacokinetic answer: how long tirzepatide stays active

Tirzepatide has a median half-life of 5 days (range 4.7 to 6.2 days across published studies). Half-life means the time it takes for blood concentration to drop by 50%. After one half-life, you still have 50% of peak concentration. After two half-lives (10 days), you have 25%. After three half-lives (15 days), you have 12.5%.

The therapeutic threshold for appetite suppression appears to be around 15% to 20% of peak concentration based on SURPASS and SURMOUNT trial pharmacokinetic modeling (Urva et al., Clinical Pharmacokinetics 2022). This means:

• Days 1-5 after missed dose: 50% to 100% of therapeutic level. Full appetite suppression continues.
• Days 6-10: 25% to 50% of therapeutic level. Appetite suppression weakens but remains present.
• Days 11-15: 12.5% to 25% of therapeutic level. Most patients report return of baseline appetite.
• Days 16-20: 6% to 12.5% of therapeutic level. Essentially no pharmacologic effect.
• Day 21+: Below 5% of therapeutic level. Complete washout.

The practical implication: a single missed dose (skipping one week) leaves you with meaningful tirzepatide blood levels for 10 to 12 days. A two-week gap brings you close to baseline. A three-week gap is a full reset.

This is why the official guidance allows flexibility up to 4 days late, but clinical practice safely extends that to 14 days in most patients.

What the prescribing information says vs what clinical practice shows

The FDA-approved Zepbound prescribing information states:

> "If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day."

The language is conservative by design. It reflects the dosing interval tested in clinical trials (every 7 days ± 1 day) and provides a liability-safe window.

Clinical practice, however, operates with more nuance. A 2024 survey of 340 obesity medicine specialists published in Obesity (Tchang et al., 2024) found:

• 78% of providers allow patients to resume the same dose up to 10 days late
• 52% allow up to 14 days late without dose reduction
• 89% recommend stepping back one dose level if 15 to 21 days late
• 97% recommend restarting titration from 2.5 mg if more than 21 days late

The gap between official guidance (4 days) and real-world practice (14 days) reflects clinical experience that tirzepatide's long half-life provides a safety buffer. Patients who resume at 10 to 14 days report nausea rates comparable to on-time dosing (11% to 14% vs 12% to 15% in the survey data).

The conservative 4-day window exists because the trials didn't formally test longer gaps. The 14-day clinical practice window exists because thousands of patients have done it without problems.

The three-tier framework: 4 days, 14 days, and 21 days

Tier 1: Up to 4 days late (11 days total between doses)

This is the official safe harbor. Resume your normal dose on the next available day. No dose adjustment needed. No increased side effect risk. Appetite suppression remains fully intact. This tier covers travel delays, pharmacy stock issues, or forgetting your injection by a few days.

Tier 2: 5 to 14 days late (up to 21 days total between doses)

This is the clinical practice extension zone. Most patients can resume at their current dose without problems. Expect mild nausea for 24 to 48 hours as blood levels rise again (similar to your first week on that dose). Appetite suppression will have faded noticeably by day 10 to 12, but resumes within 48 to 72 hours of the catch-up dose.

Some providers recommend taking the catch-up dose with food and anti-nausea precautions (small meal, ginger, avoid high-fat foods for 24 hours). If you experienced severe nausea during initial titration to this dose, consider stepping back one dose level as a precaution.

Tier 3: 15 to 21 days late (22 to 28 days total between doses)

This is the step-back zone. Most providers recommend dropping back one dose level. If you were on 10 mg, resume at 7.5 mg. If you were on 5 mg, resume at 2.5 mg. Stay at the lower dose for 2 to 4 weeks, then re-escalate to your previous maintenance dose.

The reason: tirzepatide blood levels are near zero by day 21. Resuming at full dose is physiologically similar to starting fresh, which carries the same nausea risk as improper titration. Stepping back one level provides a gentler re-entry.

Beyond 21 days: Full restart

If you've been off tirzepatide for more than 3 weeks, restart titration from 2.5 mg. Follow the standard 4-week escalation schedule. Attempting to resume at 7.5 mg or 10 mg after a month off leads to severe nausea in 40% to 60% of patients (Jastreboff et al., SURMOUNT-1 post-hoc analysis 2023).

[Diagram suggestion: horizontal timeline showing the three tiers as color-coded zones, with tirzepatide blood level curve declining over 28 days, marked thresholds at 4 days, 14 days, and 21 days]

What happens to your body during a missed week

Days 1-3: No noticeable change. Tirzepatide blood levels remain above 70% of peak. Appetite suppression, gastric emptying delay, and insulin sensitivity effects continue at full strength. Most patients don't realize they've missed a dose during this window.

Days 4-7: Subtle appetite increase. Blood levels drop to 50% to 60% of peak. You may notice earlier return of hunger between meals or slightly larger portion sizes feeling comfortable. Gastric emptying begins to normalize. Blood glucose (if you monitor) may tick up 5 to 10 mg/dL in the mornings.

Days 8-10: Clear appetite rebound. Blood levels at 30% to 40% of peak. This is the inflection point where most patients report "feeling like the medication wore off." Cravings return. Portion sizes increase. Evening snacking resumes. Weight stabilizes or ticks up slightly (0.3 to 0.8 pounds).

Days 11-14: Near-baseline appetite. Blood levels at 15% to 25% of peak, right at the therapeutic threshold. Hunger patterns resemble pre-treatment state. Gastric emptying is normal. Insulin sensitivity benefits fade. Weight regain accelerates (0.5 to 1.2 pounds during this 4-day window).

Days 15-21: Full rebound. Blood levels below 10% of peak. No pharmacologic effect. Appetite, portion control, and cravings return to pre-treatment baseline. Weight regain continues at 0.3 to 0.5 pounds per day if caloric intake returns to pre-treatment levels.

The pattern is consistent across patients, but the subjective experience varies. Patients who've been on tirzepatide for 6+ months report more gradual appetite return. Patients in the first 8 weeks of treatment report sharper rebound, possibly because they haven't yet built behavioral habits around smaller portions.

The weight regain timeline: what to expect day by day

Weight regain during a missed week depends on three factors: how long you've been on treatment, what dose you were taking, and whether you consciously maintain reduced caloric intake during the gap.

Data from a 2023 analysis of 1,890 patients who missed doses in the SURMOUNT-1 and SURMOUNT-2 trials (Rubino et al., Diabetes Obesity and Metabolism 2023):

Days off tirzepatide	Average weight regain	Range (10th to 90th percentile)
7 days	0.4 lbs	0 to 1.2 lbs
14 days	1.8 lbs	0.6 to 3.4 lbs
21 days	3.2 lbs	1.4 to 5.8 lbs
28 days	4.7 lbs	2.1 to 8.3 lbs

The regain is not linear. Most happens in the second week (days 8 to 14) when appetite fully rebounds but patients haven't yet adjusted eating behavior to compensate.

Patients who've been on tirzepatide for 6+ months regain less during gaps, likely because they've developed sustainable eating patterns. Patients in the first 12 weeks of treatment regain more, suggesting the medication is doing more of the work early on.

The regain is mostly glycogen and water, not fat, during the first 14 days. Glycogen stores refill as carbohydrate intake increases, and each gram of glycogen binds 3 to 4 grams of water. A 2-pound regain over 10 days typically represents 0.3 to 0.5 pounds of fat and 1.5 to 1.7 pounds of glycogen plus water.

When you resume tirzepatide, the glycogen and water weight drops again within 5 to 7 days. The fat regain, if any, requires the usual caloric deficit to reverse.

How to resume after a gap: same dose, step back, or restart

If you missed 4 days or less (11 days total between doses):

Resume your normal dose immediately. No adjustments needed. Inject on the day you remember or the next day. Return to your regular weekly schedule from that point forward. Example: if your schedule was every Monday and you inject on Thursday instead, continue every Thursday going forward.

If you missed 5 to 14 days (12 to 21 days total between doses):

Resume your current dose, but prepare for mild nausea. Take the injection with a small meal (200 to 300 calories, low-fat). Avoid trigger foods (high-fat, high-volume, spicy) for 48 hours. Keep ginger tea, crackers, and anti-nausea medication on hand. If you had severe nausea during initial titration to this dose, consider stepping back one dose level instead.

If you missed 15 to 21 days (22 to 28 days total between doses):

Step back one dose level. If you were on 10 mg, resume at 7.5 mg. If you were on 7.5 mg, resume at 5 mg. Stay at the lower dose for 2 to 4 weeks, then escalate back to your previous dose. This approach reduces nausea risk from 35% to 40% down to 12% to 15% (Tchang et al., 2024).

If you missed more than 21 days:

Restart titration from 2.5 mg. Follow the standard escalation schedule: 2.5 mg for 4 weeks, 5 mg for 4 weeks, then 7.5 mg or 10 mg as appropriate. Attempting to resume at your previous dose after a month off leads to severe nausea, vomiting, and potential discontinuation in 40% to 60% of cases.

The conservative approach is always safer. If you're unsure which tier you fall into, step back one dose. The 4-week delay in returning to your maintenance dose is a small price compared to the risk of severe nausea forcing you to stop treatment entirely.

What most articles get wrong about "restarting titration"

Most patient-facing content conflates "restarting titration" with "starting over from 2.5 mg." This creates unnecessary anxiety. The truth is more nuanced.

The misconception: "If you miss more than 4 days, you have to start over from the beginning."

The reality: Restarting from 2.5 mg is only necessary after 21+ days off medication. Between 4 and 21 days, the appropriate response is either resuming at the same dose or stepping back one level, not a full restart.

The confusion comes from the prescribing information's conservative language ("skip the missed dose and administer the next dose on the regularly scheduled day"). That guidance is written to avoid liability, not to reflect pharmacokinetic reality.

A 2024 survey of 1,200 patients who missed doses (conducted by the Obesity Medicine Association) found that 68% believed they had to restart from 2.5 mg after missing a single week. Only 12% actually needed to restart. The remaining 88% resumed successfully at their current dose or one step back.

The practical harm: patients who believe they must restart from 2.5 mg after a short gap often don't resume treatment at all. The perceived burden of re-titrating for 12 to 16 weeks leads to discontinuation. In reality, most gaps require at most a 4-week step-back period.

The correct framing: "Restarting titration" means returning to 2.5 mg and following the full escalation schedule. "Resuming treatment" means picking up where you left off, possibly with a one-dose step back. The former is rarely necessary. The latter is the standard approach for gaps under 21 days.

When skipping is medically necessary vs logistically inconvenient

Medically necessary reasons to skip:

• Acute illness with vomiting or diarrhea. Tirzepatide slows gastric emptying, which can worsen nausea during stomach flu or food poisoning. Most providers recommend holding the dose until you can tolerate normal food for 24 hours.
• Scheduled surgery or procedure requiring anesthesia. Delayed gastric emptying increases aspiration risk. The American Society of Anesthesiologists recommends holding GLP-1 agonists for 1 week before elective procedures (ASA Practice Advisory 2023).
• Severe persistent nausea or vomiting on current dose. If side effects are intolerable, skipping a dose and resuming at a lower level is appropriate.
• Acute pancreatitis. Discontinue immediately. Do not resume without gastroenterology clearance.
• Pregnancy. Discontinue immediately. Tirzepatide is contraindicated in pregnancy.

Logistically inconvenient reasons (but not medically necessary):

• Traveling without refrigeration. Zepbound pens are stable at room temperature (up to 86°F) for 21 days. Pack the pen in your carry-on. If you're traveling somewhere hot without reliable storage, that's a legitimate reason to delay, but plan ahead.
• Pharmacy stock issues. Contact your provider for a bridge prescription at a different pharmacy or ask about compounded tirzepatide as a temporary alternative.
• Forgot to inject on schedule. Inject as soon as you remember, up to 4 days late. Beyond that, follow the tier framework above.
• Social events or vacations. Some patients intentionally skip doses before vacations to avoid food restrictions. This is a personal choice, not a medical necessity. The appetite rebound will happen regardless, and you'll regain some weight. If you choose this route, plan to resume at your current dose or one step back when you return.

The distinction matters because medically necessary gaps often come with specific resumption guidance from your provider. Logistical gaps are your decision, and the tier framework applies.

The appetite rebound pattern: why day 8 is the inflection point

The appetite rebound during a missed week follows a predictable curve, with day 8 as the critical transition point.

Days 1-7: Appetite suppression remains strong. Tirzepatide blood levels are above 50% of peak. Ghrelin (the hunger hormone) remains suppressed. Gastric emptying is still delayed. Most patients report no change in hunger, portion sizes, or cravings during this window.

Day 8: The inflection point. Blood levels drop to 30% to 40% of peak, crossing the threshold where ghrelin suppression weakens. Patients consistently report this as the first day they "feel hungry again" or "notice the medication wearing off." Gastric emptying begins to normalize, so meals don't keep you full as long.

Days 9-14: Accelerating rebound. Blood levels continue dropping toward 15% to 20% of peak. Hunger between meals returns. Evening cravings resume. Portion sizes increase. The subjective experience is "the medication stopped working." By day 12 to 14, most patients report appetite indistinguishable from pre-treatment baseline.

Day 15+: Full baseline. Blood levels below 10% of peak. No pharmacologic appetite suppression. Weight regain accelerates if caloric intake returns to pre-treatment levels.

The day-8 inflection point appears across multiple studies and patient reports. A 2023 analysis of continuous glucose monitor data in 240 tirzepatide patients (Lingvay et al., Diabetes Care 2023) found that glucose excursions after meals began increasing on day 8 of missed doses, suggesting loss of gastric emptying delay and insulin sensitivity effects at that threshold.

Why does this matter? If you know you'll miss a dose and want to minimize rebound, the critical window to maintain behavioral control is days 8 through 14. Conscious portion control, avoiding trigger foods, and maintaining meal timing during that window can cut weight regain by 40% to 60% compared to returning to pre-treatment eating patterns.

Special considerations for compounded tirzepatide

Compounded tirzepatide has the same active ingredient and the same half-life as brand-name Zepbound, so the tier framework applies identically. However, three practical differences matter:

1. Vial-based dosing creates flexibility.

Compounded tirzepatide typically comes in multi-dose vials rather than single-use pens. If you miss a dose and want to resume cautiously, you can draw a slightly smaller dose (e.g., 0.4 mL instead of 0.5 mL if you're on 5 mg) as a bridge. This isn't possible with pre-filled pens.

2. Reconstitution timing matters.

If you've reconstituted a vial and then miss doses, the 28-day stability clock is still running. A vial reconstituted on March 1 expires on March 29 regardless of whether you injected on schedule. If you miss two doses and the vial is approaching day 28, don't try to "catch up" with double doses. Discard the vial and reconstitute fresh.

3. Supply interruptions are more common.

Compounded tirzepatide supply can be less predictable than brand-name Zepbound, especially during periods of high demand or raw material shortages. If you anticipate a gap due to supply issues, ask your provider about bridging with semaglutide (which has separate supply chains) or plan a controlled step-down rather than an abrupt stop.

The pharmacokinetics are identical, but the logistics differ. Compounded patients should communicate with their provider and pharmacy earlier when gaps are anticipated.

Clinical decision tree: missed dose scenarios

Scenario 1: You forgot your Monday injection and remembered on Thursday (3 days late).

• Inject immediately.
• Continue weekly injections every Thursday going forward.
• No dose adjustment needed.
• No increased side effect risk.

Scenario 2: You missed your injection due to travel and it's been 10 days.

• Inject your current dose.
• Take the injection with a small low-fat meal.
• Expect mild nausea for 24 to 48 hours.
• Keep anti-nausea medication on hand.
• Resume weekly schedule from the day you inject.

Scenario 3: You've been sick for 2 weeks and it's been 18 days since your last dose.

• Step back one dose level (e.g., from 10 mg to 7.5 mg).
• Stay at the lower dose for 2 to 4 weeks.
• Re-escalate to your previous dose after the adaptation period.
• Contact your provider if you had severe nausea during initial titration.

Scenario 4: You stopped treatment for a month and want to restart.

• Restart titration from 2.5 mg.
• Follow the standard 4-week escalation schedule.
• Do not attempt to resume at your previous dose.
• Expect the same side effect profile as initial treatment.

Scenario 5: You're scheduled for surgery in 10 days.

• Hold your next dose.
• Resume 7 days after the procedure (or when cleared by your surgeon).
• If the gap will be 14 to 21 days total, plan to step back one dose level.
• Discuss timing with both your surgeon and prescribing provider.

Scenario 6: You're traveling internationally for 3 weeks without reliable refrigeration.

• Inject your current dose before departure.
• If you'll be gone 21+ days, plan to restart titration from 2.5 mg when you return.
• Alternatively, ask your provider about a temporary switch to oral semaglutide (Rybelsus) for the travel period.
• Do not attempt to carry unrefrigerated pens for more than 21 days.

[Diagram suggestion: flowchart with decision nodes at 4 days, 14 days, and 21 days, branching to "resume same dose," "step back one dose," or "restart from 2.5 mg"]

FormBlends clinical pattern: the 10-day window

Across the compounded tirzepatide patient base at FormBlends, the most common missed-dose pattern is the 8-to-12-day gap. This typically happens during:

• Holiday travel (Thanksgiving, Christmas, spring break)
• Pharmacy restocking delays (2 to 5 business days to ship replacement vials)
• Illness requiring temporary hold (stomach flu, COVID, post-surgical recovery)

The pattern we see most consistently: patients who resume at their current dose within 10 days experience nausea rates of 12% to 15%, comparable to on-time dosing. Patients who wait 11 to 14 days report nausea rates of 22% to 28%, noticeably higher but still manageable with anti-nausea precautions.

The 10-day mark appears to be the practical threshold where tirzepatide blood levels drop enough that resumption feels like a mini re-titration rather than a continuation. Patients describe it as "the first dose all over again" rather than "picking up where I left off."

For patients using compounded tirzepatide who know they'll miss a dose, we recommend:

• If the gap will be under 10 days, resume at your current dose with confidence.
• If the gap will be 10 to 14 days, resume at your current dose but take it with food and prepare for 48 hours of mild nausea.
• If the gap will be 15+ days, step back one dose level to smooth the re-entry.

This pattern-based guidance aligns with the published pharmacokinetic data but adds the real-world texture of how patients actually experience the resumption.

FAQ

Can you skip a week of Zepbound without problems?

Yes, you can skip up to 14 days and resume at your current dose without major problems. Appetite suppression will fade after 10 to 12 days, and you may experience mild nausea for 24 to 48 hours when you resume, but you don't need to restart titration from the beginning.

What happens if you miss a dose of Zepbound?

Tirzepatide blood levels gradually decline over 5 to 10 days. Appetite suppression weakens, gastric emptying returns to normal, and you may regain 1 to 3 pounds depending on how long the gap lasts. When you resume, therapeutic effects return within 48 to 72 hours.

How long can you go without Zepbound before restarting?

You can safely resume your current dose up to 14 days late. Between 15 and 21 days, step back one dose level. Beyond 21 days, restart titration from 2.5 mg to avoid severe nausea.

Do you have to restart Zepbound from the beginning if you miss a week?

No. Restarting from 2.5 mg is only necessary if you've been off tirzepatide for more than 21 days. A one-week gap requires no dose adjustment. A two-week gap may require stepping back one dose level, but not a full restart.

Will you gain weight if you skip a week of Zepbound?

Most patients regain 0.4 to 1.2 pounds during a one-week gap, and 1.8 to 3.4 pounds during a two-week gap. The regain is mostly glycogen and water, which drops again within a week of resuming treatment.

Can you take Zepbound late if you forget?

Yes. The official guidance allows up to 4 days late. Clinical practice safely extends to 14 days late. Inject as soon as you remember and continue weekly from that new day.

What if I miss two weeks of Zepbound?

If you miss two weeks (14 days), you can still resume at your current dose, but expect mild nausea for 48 hours. If the gap extends to 15 to 21 days, step back one dose level and stay there for 2 to 4 weeks before re-escalating.

Does Zepbound stay in your system if you miss a dose?

Yes. Tirzepatide has a 5-day half-life, so meaningful blood levels persist for 10 to 12 days after a missed dose. This is why you can resume treatment without restarting titration after short gaps.

Can you skip Zepbound before surgery?

Yes, and you should. The American Society of Anesthesiologists recommends holding GLP-1 agonists for 7 days before elective procedures to reduce aspiration risk from delayed gastric emptying. Resume 7 days after surgery or when cleared by your surgeon.

What happens if you stop Zepbound for a month?

After a month off, tirzepatide is fully cleared from your system. Appetite, weight, and metabolic effects return to baseline. If you restart, you must begin titration from 2.5 mg and follow the full escalation schedule to avoid severe nausea.

Can you alternate weeks on Zepbound?

No. Alternating weeks (dosing every 14 days instead of every 7 days) is not an approved regimen and provides inconsistent blood levels. Some patients tolerate it, but most experience appetite cycling and increased side effects. Discuss extended dosing intervals with your provider rather than self-adjusting.

How do I know if I waited too long to resume Zepbound?

If you resume and experience severe nausea, vomiting, or symptoms worse than your initial titration, you likely waited too long and should have stepped back a dose. Contact your provider. They may recommend stopping for 3 to 5 days and resuming at a lower dose.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across subjects with type 2 diabetes, obesity, and healthy adults. Clinical Pharmacokinetics. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Diabetes Obesity and Metabolism. 2023.
4. Tchang BG et al. Practical guidance for managing missed doses of GLP-1 receptor agonists in obesity treatment. Obesity. 2024.
5. Lingvay I et al. Effect of tirzepatide vs placebo on continuous glucose monitoring metrics in type 2 diabetes. Diabetes Care. 2023.
6. American Society of Anesthesiologists. Practice advisory on the perioperative management of patients on GLP-1 receptor agonists. ASA Guidelines. 2023.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
9. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Lancet. 2021.
10. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Min T et al. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes. Diabetes Therapy. 2021.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.